Literature DB >> 17120479

Acute ischaemic stroke treated with combined intra-arterial thrombolysis and intravenous tirofiban despite oral anticoagulant therapy at an international normalised ratio > or = 2.0.

Stefano Del Pace, Valentina Scheggi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17120479     DOI: 10.1007/bf02934752

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  5 in total

1.  Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study.

Authors: 
Journal:  Stroke       Date:  2000-03       Impact factor: 7.914

2.  Combined direct percutaneous transluminal angioplasty and low-dose native tissue plasminogen activator therapy for acute embolic middle cerebral artery trunk occlusion.

Authors:  Takumi Yoneyama; Shinichi Nakano; Hirokazu Kawano; Tsutomu Iseda; Tokuro Ikeda; Tomokazu Goya; Shinichiro Wakisaka
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

3.  Acute basilar artery occlusion treated with combined intravenous Abciximab and intra-arterial tissue plasminogen activator: report of 3 cases.

Authors:  Bernd Eckert; Christoph Koch; Götz Thomalla; Joachim Roether; Herrmann Zeumer
Journal:  Stroke       Date:  2002-05       Impact factor: 7.914

4.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

Authors:  E J Topol
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

5.  Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Authors:  Randall T Higashida; Anthony J Furlan; Heidi Roberts; Thomas Tomsick; Buddy Connors; John Barr; William Dillon; Steven Warach; Joseph Broderick; Barbara Tilley; David Sacks
Journal:  Stroke       Date:  2003-07-17       Impact factor: 7.914

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.